Polyclinique Bordeaux Nord Aquitaine — Clinical Trial Site

61 Registered trials

24 Currently recruiting

Organisation

Polyclinique Bordeaux Nord Aquitaine

Location

Bordeaux Cedex, France

Identifier

ORG-100041518

Address

33 Rue Docteur Finlay, 33300, France

Departments

Gastroenterology
Hemato Onco-radiothérapie
Hematology
Hepato-Gastro-Entérology
Hépato-gastroentérologie et oncologie digestive
Hepatogastroenterology
Medical Oncology
Medical Oncology Department
Oncologie
Oncologie - Radiothérapie
Oncologie Médicale
Oncologie Radiothérapie
Oncology
oncology department
Oncology Radiotherapy Unit
Oncology-Radiotherapy
Radiothérapie
Radiotherapy
Service d'Oncologie - Radiothérapie
Service d'Oncologie Médicale
Service d'oncologie, Radiothérapie
service d'oncologie, Radiothérapie, Service de chimiothérapie
Service de Pneumologie
Service de radiothérapie
Service Oncologie
Service Radiothérapie
Urologie

Clinical trials at this site (61)

Search interface

Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Newly diagnosed Diffuse Large B Cell Lymphoma 7 2016-09-19
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Non small cell lung cancer 5 2018-05-02
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Triple Negative Breast Cancer (TNBC) 5 2017-03-07
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Completely resected primary stage IB (≥ 4cm), II and II 5 2015-03-09
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati… Ended

2023-509227-41-00 Low risk of disease recurrence, defined by the followin 4
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4